CHA₂DS₂-VASc Score Calculator

What Is the CHA₂DS₂-VASc Score?

The CHA₂DS₂-VASc Score is a clinical prediction tool used to estimate the annual risk of stroke in patients with non-valvular atrial fibrillation (AF). It was developed by Lip et al. in 2010 as a refinement of the earlier CHADS₂ score, adding additional risk factors to improve risk stratification, particularly for patients previously classified as "low risk."

Atrial fibrillation is the most common cardiac arrhythmia, affecting an estimated 33 million people worldwide. AF significantly increases the risk of ischemic stroke by allowing blood to pool in the left atrial appendage, forming clots that can embolize to the brain. The CHA₂DS₂-VASc score helps identify which AF patients benefit from anticoagulation therapy to prevent these strokes.

Scoring Components

The acronym CHA₂DS₂-VASc stands for the following risk factors:

Letter	Risk Factor	Points
C	Congestive Heart Failure (or LVEF ≤40%)	1
H	Hypertension	1
A₂	Age ≥ 75 years	2
D	Diabetes Mellitus	1
S₂	Prior Stroke / TIA / Thromboembolism	2
V	Vascular Disease (MI, PAD, aortic plaque)	1
A	Age 65–74 years	1
Sc	Sex Category (Female)	1

The maximum possible score is 9 (since age categories are mutually exclusive).

Stroke Risk by Score

Based on the landmark study by Lip et al. (2010) using data from the Euro Heart Survey on Atrial Fibrillation:

CHA₂DS₂-VASc Score	Adjusted Stroke Rate (%/year)
0	0%
1	1.3%
2	2.2%
3	3.2%
4	4.0%
5	6.7%
6	9.8%
7	9.6%
8	6.7%
9	15.2%

Treatment Recommendations

Score = 0 (Males) or 1 (Females with sole risk factor = sex)

No anticoagulation therapy recommended. The risk of stroke is very low, and the bleeding risk from anticoagulation outweighs the benefit. Reassess periodically as risk factors may develop over time.

Score = 1 (Males) or 2 (Females)

Consider oral anticoagulation. The decision should be individualized based on patient preferences, bleeding risk (HAS-BLED score), and other clinical factors. Options include DOACs (dabigatran, rivaroxaban, apixaban, edoxaban) or warfarin.

Score ≥ 2 (Males) or ≥ 3 (Females)

Oral anticoagulation is recommended. Direct Oral Anticoagulants (DOACs) are preferred over warfarin in most patients due to fewer drug interactions, no need for routine INR monitoring, and lower risk of intracranial hemorrhage.

CHA₂DS₂-VASc vs CHADS₂

Feature	CHADS₂	CHA₂DS₂-VASc
Year Introduced	2001	2010
Maximum Score	6	9
Vascular Disease	Not included	Included (+1)
Age Categories	Age ≥75 only	65–74 (+1) and ≥75 (+2)
Sex	Not included	Female (+1)
Low-risk Identification	Poor	Better

The CHA₂DS₂-VASc score is now the preferred tool in ESC, AHA/ACC, and most international guidelines for stroke risk assessment in AF patients.

Important Considerations

The Female Sex Controversy

Female sex is considered a "risk modifier" rather than an independent risk factor. A woman with no other risk factors (score of 1 from sex alone) is still considered low-risk and typically does not need anticoagulation. The female sex point becomes clinically significant when combined with at least one other risk factor.

Bleeding Risk Assessment

Before starting anticoagulation, assess bleeding risk using the HAS-BLED score (Hypertension, Abnormal renal/liver function, Stroke, Bleeding, Labile INR, Elderly, Drugs/alcohol). A high HAS-BLED score does not necessarily preclude anticoagulation but warrants closer monitoring and modifiable risk factor correction.

Frequently Asked Questions

What score requires anticoagulation?

For males, a CHA₂DS₂-VASc score ≥2 generally warrants oral anticoagulation. For females, ≥3 (since one point comes from sex alone). A score of 1 in males or 2 in females is a "grey zone" where the decision should be individualized.

Which anticoagulant is best?

DOACs (dabigatran, rivaroxaban, apixaban, edoxaban) are preferred over warfarin for most AF patients. Warfarin remains the choice for patients with mechanical heart valves or moderate-to-severe mitral stenosis (valvular AF).

Can the CHA₂DS₂-VASc score be used for atrial flutter?

Yes. Most guidelines recommend using the same stroke risk assessment and anticoagulation approach for atrial flutter as for atrial fibrillation, since the thromboembolic risk is similar.

Does aspirin prevent stroke in AF?

Aspirin is no longer recommended for stroke prevention in AF. Clinical trials have shown that aspirin provides minimal stroke reduction while still carrying significant bleeding risk. Current guidelines recommend either no antithrombotic therapy (low risk) or oral anticoagulation (moderate-high risk).